Pascale Witz, President and CEO, GE Healthcare, Medical Diagnostics discussed diagnostics as the future of personalized medicine at the 30th JP Morgan Healthcare Conference in San Francisco, CA. During her presentation, Witz noted that diagnostics and pathology screening are core enablers of personalized medicine, and outlined how GE Healthcare partners with the pharmaceutical industry to support market entry of new therapies via providing complex technologies that can aid in the conduct of clinical trials, potentially expediting time to market.

“Personalized medicine is at the core of our efforts in medical diagnostics,” Witz said. “We are working to combine in vivo and in vitro testing for integrated solutions from risk stratification and early detection through prediction and monitoring. The combination of our different business offerings positions us well to offer an integrated global diagnostics solution for the next generation of therapies.”

Witz’s talk focused specifically on GE Healthcare’s existing work in oncology and the Company’s commitment to expand its advanced cancer diagnostic and molecular imaging capabilities. With its advanced technologies, GE Healthcare’s Clarient business is able to provide pathologists and oncologists with accurate and detailed information to help characterize and assess cancer which may lead to more accurate diagnoses and more effective treatment. Witz also discussed Omnyx, a joint venture between GE Healthcare and the University of Pittsburgh, which is developing an Integrated Digital Pathology system allowing pathology departments worldwide to move to an all-digital workflow.

A link to Witz’s presentation is available at GE’s Investor Relations website at http://www.ge.com/investors/events/event_id01102012.html.

-Richard Park